Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Syros Pharmaceuticals
(NQ:
SYRS
)
2.000
+0.040 (+2.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate
September 13, 2022
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.
Via
Benzinga
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
September 13, 2022
From
Syros Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 13, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 13, 2022
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!
Via
InvestorPlace
TYME Technologies Shares Surge On Merger Agreement With Syros Pharma
July 05, 2022
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket
September 13, 2022
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average...
Via
Benzinga
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
What 4 Analyst Ratings Have To Say About Syros Pharmaceuticals
August 10, 2022
Analysts have provided the following ratings for Syros Pharmaceuticals (NASDAQ:SYRS) within the last quarter:
Via
Benzinga
Coinbase To $115? Plus This Analyst Cuts PT On Syros Pharmaceuticals By 67%
August 10, 2022
Deutsche Bank boosted the price target on FactSet Research Systems Inc. (NYSE: FDS) from $418 to $463. However, Deutsche Bank analyst Faiza Alwy maintained the stock with a Hold rating. FactSet...
Via
Benzinga
Citigroup Slashes Price Target On This Stock By 83%; Also Check Out Some Other Big PT Changes
August 10, 2022
RBC Capital cut the price target for Nuvei Corporation (NASDAQ: NVEI) from $80 to $60. Nuvei shares fell 21.5% to close at $33.03 on Tuesday.
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 09, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Earnings Scheduled For August 9, 2022
August 09, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Via
Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 03, 2022
Via
Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
August 04, 2022
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.
Via
Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
August 04, 2022
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 03, 2022
Gainers
Via
Benzinga
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
August 03, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
August 02, 2022
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
July 08, 2022
Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
July 05, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed
June 21, 2022
Syros Pharmaceuticals (NASDAQ:SYRS) brought in sales totaling $5.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 5.6%, resulting in a loss of $25.15...
Via
Benzinga
Syros to Present at JMP Securities Life Sciences Conference
June 08, 2022
From
Syros Pharmaceuticals
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.